The neuroprotective effect of erythropoietin on experimental Parkinson model in rats

Erbaş, Oytun; Cinar, Bilge Piri; Solmaz, Volkan; Çavuşoğlu, Türker; Ateş, Utku

doi:10.1016/j.npep.2014.10.003

Cited by 40 publications

(40 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EPO protects cultured rat embryonic midbrain dopamine neurons from 6--OHDA toxicity 205 , and intraperitoneal administration prevents 6--OHDA--induced loss of SN dopamine neurons, reduces apomorphine--induced rotations in unilateral 6--OHDA--lesioned rats, and inhibits the activation of the caspase--3 signaling pathway in this in vivo model of PD 206 . Similar neuroprotection was seen in the rat rotenone model of PD 207 . Although EPO has clear neuroprotective activity for PD and other CNS diseases, it also has a possibility of causing systemic side effects due to its hematopoietic activity.…”

Section: Erythropoietinsupporting

confidence: 69%

intranasal GDNF gene therapy approach for treating Parkinson's disease

Aly¹

View full text Add to dashboard Cite

Abstract:Parkinson's disease (PD) is a progressive neurodegenerative disorder that results from the loss of the A9 nigrostriatal dopamine neurons. The current therapies available for treating PD provide symptomatic relief by replacing or mimicking dopamine in the brain, but do not actually prevent or reverse the loss of these dopaminergic neurons. Glial cell--line derived neurotrophic factor (GDNF) has disease--modifying potential in PD due to its ability to promote the survival of dopamine neurons both in vitro and in vivo. GDNF has been shown to be neuroprotective in several animal models of PD. However, its clinical potential has been limited thus far by its inability to cross the blood--brain barrier (BBB) and the need for invasive intracranial delivery. The main objective of this thesis was to develop an approach to non--invasively deliver a continuous source of GDNF to the brain at levels that are neuroprotective inParkinson's Disease, whilst minimizing systemic exposure. To do so, this project investigated the intranasal delivery of non--viral hGDNF expression plasmids (pGDNF_1b and pUGG) compacted into nanoparticles (NPs). Intranasal delivery allows large therapeutics to circumvent the BBB while avoiding peripheral exposure, while a gene therapy approach would provide a long--term renewable source of GDNF in the brain regions associated with PD. These NPs, developed by Copernicus Therapeutics, Inc., are composed of 10 kDa polyethylene glycol--substituted lysine 30--mers (CK30PEG10k) which unimolecularly compact the plasmid DNA into neutrally charged NPs.The first goal of this project was to determine if intranasal administration of pGDNF_1b DNA NPs produces a neuroprotective and neurotrophic effect on rat substantia nigra (SN)

show abstract

Section: Erythropoietinsupporting

confidence: 69%

intranasal GDNF gene therapy approach for treating Parkinson's disease

Aly¹

View full text Add to dashboard Cite

show abstract

“…A previous report shows that EPO can inhibit 6-hydroxydopamine-induced neuron death in in vitro and in vivo models of PD through activating the phosphatidylinosito l3-kinase/Akt signalling pathway and the downstream substrate FoxO3a [46]. Furthermore, in the rat models of PD, EPO can markedly suppress apoptosis of striatal neurons and significantly improve neurological function [46]. EPO has protective and treating effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced neurotoxicity in this mouse model of Parkinson's Disease via increasing nitric oxide production [5,6].…”

Section: Introductionmentioning

confidence: 98%

“…Currently, EPO has been regard as a potential therapeutic candidate for treatment of PD due to its neuroprotective effects [14,[17][18][19][20][21][22][23][24][25][26]. Some preclinical studies has been done in order to observe the neuroprotective effects of EPO treatment of PD [5,6,45,46]. A previous report shows that EPO can inhibit 6-hydroxydopamine-induced neuron death in in vitro and in vivo models of PD through activating the phosphatidylinosito l3-kinase/Akt signalling pathway and the downstream substrate FoxO3a [46].…”

Section: Introductionmentioning

confidence: 99%

“…Some preclinical studies has been done in order to observe the neuroprotective effects of EPO treatment of PD [5,6,45,46]. A previous report shows that EPO can inhibit 6-hydroxydopamine-induced neuron death in in vitro and in vivo models of PD through activating the phosphatidylinosito l3-kinase/Akt signalling pathway and the downstream substrate FoxO3a [46]. Furthermore, in the rat models of PD, EPO can markedly suppress apoptosis of striatal neurons and significantly improve neurological function [46].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Point of View about Erythropoietin in Treatment of Central Nervous System Diseases

Yang¹,

Li²,

Wu³

et al. 2017

J Alzheimers Dis Parkinsonism

View full text Add to dashboard Cite

“…These growth factors, significantly, have been considered in the management of many different neurodegenerative disorders with unknown definite treatment such as stroke [3,4], Alzheimer disease [5][6][7], Parkinson [8,9]. Both G-CSF and EPO have a noticeable role in central nervous system.…”

mentioning

confidence: 99%

Therapeutic Potential of Hematopoietic Growth Factors for Treatment of Carbon Monoxide Neurotoxicity

Gholami¹

2016

Med chem

View full text Add to dashboard Cite

The neuroprotective effect of erythropoietin on experimental Parkinson model in rats

Cited by 40 publications

References 35 publications

intranasal GDNF gene therapy approach for treating Parkinson's disease

intranasal GDNF gene therapy approach for treating Parkinson's disease

Point of View about Erythropoietin in Treatment of Central Nervous System Diseases

Therapeutic Potential of Hematopoietic Growth Factors for Treatment of Carbon Monoxide Neurotoxicity

Contact Info

Product

Resources

About